The company’s partner Kelun-Biotech reported positive late-stage trial results for a Keytruda combination treatment in lung cancer.
The TroFuse-005 trial involved 776 patients with endometrial cancer whose disease worsened after receiving both platinum ...
The TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) demonstrated a statistically significant ...
Uterine cancer is the deadliest cancer of the female reproductive system. Currently, clinicians treat the disease by using a ...
Merck (NYSE:MRK) reported positive Phase 3 results for its antibody drug conjugate sacituzumab tirumotecan in advanced ...
Please provide your email address to receive an email when new articles are posted on . Sacituzumab govitecan did not improve PFS in HR-positive, HER2-negative breast cancer after endocrine therapy.
MSD's TROP2-targeting antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT), licensed from China's Kelun-Biotech, has improved survival in a late-stage endometrial cancer trial. The positive ...
Please provide your email address to receive an email when new articles are posted on . First-line sacituzumab govitecan significantly improved PFS for metastatic triple-negative breast cancer subset ...
The TROP-2–directed antibody drug conjugate is currently being investigated as a monotherapy and a combination therapy for non–small cell lung cancer (NSCLC) in 3 trials: phase 3 EVOKE-01, phase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results